Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Overexpression of the human multidrug resistance gene 1 (MDR1) is a negative prognostic factor in leukemia. Despite intense efforts to characterize the gene at the molecular level, little is known about the genetic events that switch on gene expression in P-glycoprotein-negative cells. Recent studies have shown that the transcriptional competence of MDR1 is often closely associated with DNA methylation. Chromatin remodeling and modification targeted by the recognition of methylated DNA provide a dominant mechanism for transcriptional repression. Consistent with this epigenetic model, interference with DNA methyltransferase and histone deacetylase activity alone or in combination can reactivate silent genes. In the present study, we used chromatin immunoprecipitation to monitor the molecular events involved in the activation and repression of MDR1. Inhibitors of DNA methyltransferase (5-azacytidine [5aC]) and histone deacetylase (trichostatin A [TSA]) were used to examine gene transcription, promoter methylation status, and the chromatin determinants associated with the MDR1 promoter. We have established that methyl-CpG binding protein 2 (MeCP2) is involved in methylation-dependent silencing of human MDR1 in cells that lack the known transcriptional repressors MBD2 and MBD3. In the repressed state the MDR1 promoter is methylated and assembled into chromatin enriched with MeCP2 and deacetylated histone. TSA induced significant acetylation of histones H3 and H4 but did not activate transcription. 5aC induced DNA demethylation, leading to the release of MeCP2, promoter acetylation, and partial relief of repression. MDR1 expression was significantly increased following combined 5aC and TSA treatments. Inhibition of histone deacetylase is not an overriding mechanism in the reactivation of methylated MDR1. Our results provide us with a clearer understanding of the molecular mechanism necessary for repression of MDR1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, J. D., Meehan, R. R., Henzel, W. J., Maurer-Fogy, I., Jeppesen, P., Klein, F., & Bird, A. (1992) · Cell · doi:10.1016/0092-8674(92)90610-o · Cited by 1,371
DNA methylation and chromatin modification
Ng, H.-H., & Adrian, B. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80024-0 · Cited by 648
Boyes, J., & Bird, A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05055.x · Cited by 471 · cited 2×
“Sparsely methylated genes do not provide strong ligands for MBD2/MeCP1 and therefore cannot fully repress transcription (5).”
BackgroundAcetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells
Coffee, B., Zhang, F., Warren, S. T., & Reines, D. (1999) · Nature Genetics · doi:10.1038/8807 · Cited by 325
Schübeler, D., Lorincz, M. C., Cimbora, D. M., Telling, A., Feng, Y.-Q., Bouhassira, E. E., & Groudine, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9103-9112.2000 · Cited by 165
Cited by
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726
Mild overexpression of MeCP2 causes a progressive neurological disorder in mice
Collins, A. L., Levenson, J. M., Vilaythong, A. P., Richman, R., Armstrong, D. L., Noebels, J. L., David Sweatt, J., & Zoghbi, H. Y. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh282 · Cited by 626
Young, J. I., Hong, E. P., Castle, J. C., Crespo-Barreto, J., Bowman, A. B., Rose, M. F., Kang, D., Richman, R., Johnson, J. M., Berget, S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507856102 · Cited by 484
The cancer epigenome—components and functional correlates
Ting, A. H., McGarvey, K. M., & Baylin, S. B. (2006) · Genes & Development · doi:10.1101/gad.1464906 · Cited by 419
The Role of MeCP2 in the Brain
Guy, J., Cheval, H., Selfridge, J., & Bird, A. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154121 · Cited by 418
The methyl-CpG binding domain and the evolving role of DNA methylation in animals
Hendrich, B., & Tweedie, S. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00080-5 · Cited by 399
Transcriptional regulation of ABC drug transporters
Scotto, K. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206950 · Cited by 392
Critical Role of Histone Methylation in Tumor Suppressor Gene Silencing in Colorectal Cancer
Kondo, Y., Shen, L., & Issa, J.-P. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.206-215.2003 · Cited by 346
DNA Binding Selectivity of MeCP2 Due to a Requirement for A/T Sequences Adjacent to Methyl-CpG
Klose, R. J., Sarraf, S. A., Schmiedeberg, L., McDermott, S. M., Stancheva, I., & Bird, A. P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.07.021 · Cited by 344
Epigenetic changes in colorectal cancer
Kondo, Y., & Issa, J.-P. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/a:1025806911782 · Cited by 338
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer
Ballestar, E. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg604 · Cited by 320
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing
K N, H., Chow, M. Z., Baker, E. K., Pal, S., Bassal, S., Brasacchio, D., Wang, L., Craig, J. M., Jones, P. L., Sif, S., et al. (2005) · Nature Genetics · doi:10.1038/ng1516 · Cited by 305
Self-citationEpigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
Wilting, R. H., & Dannenberg, J.-H. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.008 · Cited by 303
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197
Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs
Baker, E. K., Johnstone, R. W., Zalcberg, J. R., & El-Osta, A. (2005) · Oncogene · doi:10.1038/sj.onc.1208955 · Cited by 196
“Chromatin Immunoprecipitation ChIP was performed on CEM-CCRF, CEM-Bcl2 and SW620 cells (3.5 106), using a ChIP assay kit (Upstate Biotechnology) according to the manufacturer’s instructions, with some modifications (El-Osta et al., 2001).”
BackgroundMethodSelf-citationGenovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
The emerging role of epigenetics in cellular and organismal aging
Bandyopadhyay, D., & Medrano, E. E. (2003) · Experimental Gerontology · doi:10.1016/j.exger.2003.09.009 · Cited by 104
Epigenetics in diabetic nephropathy, immunity and metabolism
Keating, S. T., van Diepen, J. A., Riksen, N. P., & El-Osta, A. (2018) · Diabetologia · doi:10.1007/s00125-017-4490-1 · Cited by 82
“sors that assemble on chromatin recognise the methylation moiety together with other transcriptional components [95].”
BackgroundSelf-citationReed, K., Hembruff, S. L., Sprowl, J. A., & Parissenti, A. M. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.1 · Cited by 56
Metadata
- Authors
- El-Osta, A., Kantharidis, P., Zalcberg, J. R., & Wolffe, A. P.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2002-03-01
- Volume
- 22
- Issue
- 6
- Pages
- 1844-1857
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2161767853
- Cited by
- 177
- References
- 5
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.